RECRUITING

Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform across a basket of solid tumors, using in-vivo RECIST 1.1 as the reference method.

Official Title

Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (CYBRID-02)

Quick Facts

Study Start:2023-06-26
Study Completion:2027-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05520099

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Catarina Costa
CONTACT
(609) 955 4927
ClinicalTrials@elephas.com
Rebecca Mottier
CONTACT
(317) 634-5842
rmottier@hoosiercancer.org

Principal Investigator

Fred Hausheer, MD, FACP
STUDY_DIRECTOR
Elephas

Study Locations (Sites)

Salinas Valley Memorial Healthcare System
Salinas, California, 93901
United States
AdventHealth Orlando
Orlando, Florida, 32803
United States
Cleveland Clinic Florida
Stuart, Florida, 34994
United States
University of South Florida (Tampa General Hospital)
Tampa, Florida, 33606
United States
University of Louisville James Graham Brown Cancer Center
Louisville, Kentucky, 40202
United States
Meritus Health
Hagerstown, Maryland, 21742
United States
John Theurer Cancer Center
Hackensack, New Jersey, 07601
United States
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14203
United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599
United States
University of Wisconsin
Madison, Wisconsin, 53705
United States

Collaborators and Investigators

Sponsor: Elephas

  • Fred Hausheer, MD, FACP, STUDY_DIRECTOR, Elephas

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-06-26
Study Completion Date2027-01

Study Record Updates

Study Start Date2023-06-26
Study Completion Date2027-01

Terms related to this study

Keywords Provided by Researchers

  • Core Needle Biopsy
  • Live tumor fragments
  • Immunotherapy
  • Immunotherapy prediction
  • 3D culture
  • Ex vivo platform
  • Immune checkpoint inhibitors
  • Non Small Cell Lung Cancer
  • NSCLC
  • Head and Neck Squamous Cell Carcinoma
  • HNSCC
  • Clear Cell Renal Cell Carcinoma
  • ccRCC
  • Urothelial Carcinoma
  • Melanoma
  • Colon Cancer
  • Rectal Cancer
  • Endometrial Cancer
  • Forceps Biopsy
  • Metastatic solid tumor

Additional Relevant MeSH Terms

  • Colorectal Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Non Small Cell Lung Cancer
  • Cutaneous Melanoma
  • Endometrial Cancer
  • Urothelial Carcinoma
  • Clear Cell Renal Cell Carcinoma